Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | F2R | P25116 | 9/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907147 | 0.92 | TSHR (0.49) | NCOA1NCOA3LMNAF2RTSHR | |
| SCHEMBL9907158 | 0.87 | F2R (0.48) | NCOA1NCOA3LMNAF2RMEN1 | |
| SCHEMBL1205566 | 0.87 | F2R (0.42) | NCOA1NCOA3LMNAF2RMEN1 | |
| SCHEMBL1189594 | 0.86 | F2R (0.52) | NCOA1NCOA3F2R | |
| SCHEMBL1205297 | 0.86 | F2R (0.43) | NCOA1NCOA3LMNAF2RMEN1 | |
| SCHEMBL2772923 | 0.85 | TNFRSF1A (0.48) | LMNATSHRMEN1KMT2AKDM4E | |
| SCHEMBL1205281 | 0.85 | F2R (0.39) | NCOA1NCOA3LMNAF2RMEN1 | |
| SCHEMBL1728964 | 0.83 | LMNA (0.43) | NCOA1NCOA3LMNAF2RTSHR | |
| SCHEMBL1730615 | 0.83 | MEN1 (0.38) | NCOA1NCOA3LMNAF2RTSHR | |
| SCHEMBL1206118 | 0.83 | F2R (0.43) | F2RMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | NCOA1 2530/4885NCOA3 2149/4885LMNA 3366/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | NCOA1 2556/4885NCOA3 2200/4885LMNA 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.